Metabolic reprogramming in polycystic kidney disease explained by super-enhancers and CDK7: new therapeutic targets?

摘要

In this issue of Nature Metabolism, Mi and colleagues provide evidence that super-enhancers play a critical role in autosomal-dominant polycystic kidney disease (ADPKD) and show that CDK7 targeting provides a novel therapeutic option.